Tags

Type your tag names separated by a space and hit enter

Experimental therapeutics of neurodegenerative disorders: unmet needs.
Science 1998; 282(5391):1072-4Sci

Abstract

Viewpoint The experimental therapeutics of neurodegenerative disorders is in its infancy, but neuroprotective strategies are already being applied in healthy persons at high risk of developing disease as well as in patients with manifest illness. Knowledge of etiology and pathogenesis, improved design of clinical trials, the development of biological markers, the advent of genetic animal models, the enhanced identification of susceptibility factors, and more effective drug delivery-such advances have improved the prospects for forestalling onset of illness and clinical decline in the growing numbers of people affected by neurodegenerative disorders.

Authors+Show Affiliations

Department of Neurology, University of Rochester Medical Center, School of Medicine and Dentistry, Suite 212, 1351 Mt. Hope Avenue, Rochester, NY 14620, USA.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

9804537

Citation

Shoulson, I. "Experimental Therapeutics of Neurodegenerative Disorders: Unmet Needs." Science (New York, N.Y.), vol. 282, no. 5391, 1998, pp. 1072-4.
Shoulson I. Experimental therapeutics of neurodegenerative disorders: unmet needs. Science. 1998;282(5391):1072-4.
Shoulson, I. (1998). Experimental therapeutics of neurodegenerative disorders: unmet needs. Science (New York, N.Y.), 282(5391), pp. 1072-4.
Shoulson I. Experimental Therapeutics of Neurodegenerative Disorders: Unmet Needs. Science. 1998 Nov 6;282(5391):1072-4. PubMed PMID: 9804537.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Experimental therapeutics of neurodegenerative disorders: unmet needs. A1 - Shoulson,I, PY - 1998/11/6/pubmed PY - 1998/11/6/medline PY - 1998/11/6/entrez SP - 1072 EP - 4 JF - Science (New York, N.Y.) JO - Science VL - 282 IS - 5391 N2 - Viewpoint The experimental therapeutics of neurodegenerative disorders is in its infancy, but neuroprotective strategies are already being applied in healthy persons at high risk of developing disease as well as in patients with manifest illness. Knowledge of etiology and pathogenesis, improved design of clinical trials, the development of biological markers, the advent of genetic animal models, the enhanced identification of susceptibility factors, and more effective drug delivery-such advances have improved the prospects for forestalling onset of illness and clinical decline in the growing numbers of people affected by neurodegenerative disorders. SN - 0036-8075 UR - https://www.unboundmedicine.com/medline/citation/9804537/Experimental_therapeutics_of_neurodegenerative_disorders:_unmet_needs_ L2 - http://www.sciencemag.org/cgi/pmidlookup?view=long&pmid=9804537 DB - PRIME DP - Unbound Medicine ER -